Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net

Michael Girschikofsky, Maurizio Arico, Diego Castillo, Anthony Chu, Claus Doberauer, Joachim Fichter, Julien Haroche, Gregory A Kaltsas, Polyzois Makras, Angelo V Marzano, Mathilde de Menthon, Oliver Micke, Emanuela Passoni, Heinrich M Seegenschmiedt, Abdellatif Tazi, Kenneth L McClain, Michael Girschikofsky, Maurizio Arico, Diego Castillo, Anthony Chu, Claus Doberauer, Joachim Fichter, Julien Haroche, Gregory A Kaltsas, Polyzois Makras, Angelo V Marzano, Mathilde de Menthon, Oliver Micke, Emanuela Passoni, Heinrich M Seegenschmiedt, Abdellatif Tazi, Kenneth L McClain

Abstract

Langerhans Cell Histiocytosis (LCH) is an orphan disease of clonal dendritic cells which may affect any organ of the body. Most of the knowledge about the diagnosis and therapy is based on pedriatic studies. Adult LCH patients are often evaluated by physicians who focus on only the most obviously affected organ without sufficient evaluation of other systems, resulting in patients being underdiagnosed and/or incompletely staged. Furthermore they may be treated with pediatric-based therapies which are less effective and sometimes more toxic for adults. The published literature on adult LCH cases lacks a comprehensive discussion on the differences between pediatric and adult patients and there are no recommendations for evaluation and comparative therapies. In order to fill this void, a number of experts in this field cooperated to develop the first recommendations for management of adult patients with LCH. Key questions were selected according to the clinical relevance focusing on diagnostic work up, therapy, and follow up. Based on the available literature up to December 2012, recommendations were established, drafts were commented by the entire group, and redrafted by the executive editor. The quality of evidence of the recommendations is predominantly attributed to the level of expert opinion. Final agreement was by consensus.

Figures

Figure 1
Figure 1
Management of Langerhans Cell Histiocytosis in adults.

References

    1. Arico M. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003;39(16):2341–2348.
    1. Willman CL. Langerhans'-cell histiocytosis (histiocytosis X)–a clonal proliferative disease. N Engl J Med. 1994;331(3):154–160.
    1. Yousem SA. Pulmonary Langerhans' cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol. 2001;25(5):630–636.
    1. Badalian-Very G. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–1923.
    1. Badalian-Very G. Pathogenesis of Langerhans Cell Histiocytosis. Annu Rev Pathol. 2013;24(8):1–20.
    1. Egeler RM. Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer. 1993;71(3):865–873.
    1. Lee JS. Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report. J Korean Med Sci. 2006;21(3):577–580.
    1. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol. 2008;32(4):615–619.
    1. Swerdlow SHC. International Agency for Research on, Cancer and O. World Health: WHO classification of tumours of haematopoietic and lymphoid tissues . International Agency for Research on Cancer (IARC); 2008.
    1. Valladeau J. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 2000;12(1):71–81.
    1. Minkov M, Grois N, McClain K, Nanduri V, Rodriguez-Galindo C, Simonitsch-Klupp I, Visser J, Weitzmann S, Whitlock J, Windebank K. Langerhans Cell Histiocytosis - Histiocyte Society Evaluation and Treatment Guidelines. 2009. cited; Available from: .
    1. Arico M. Familial clustering of Langerhans cell histiocytosis. Br J Haematol. 1999;107(4):883–888.
    1. McClain K. Bone and Soft Tissue Involvement - Oral Presentation at the Annual Meeting of the Histiocyte Society, Vienna. 2011.
    1. Phillips M. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009;52(1):97–101.
    1. Szturz P. [Lymphoma-like course in aggressive adult multisystem Langerhans cell histiocytosis and the benefit of PET/CT imaging in evaluation of diffuse metabolic activity of lung parenchyma] Vnitr Lek. 2010;56(11):1177–1193.
    1. Teng CL. Rapidly fatal Langerhans' cell histiocytosis in an adult. J Formos Med Assoc. 2005;104(12):955–959.
    1. Grois N. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228–233.
    1. Kaltsas GA. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab. 2000;85(4):1370–1376.
    1. Prosch H. Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43(5):594–599.
    1. Makras P. Endocrine manifestations in Langerhans cell histiocytosis. Trends Endocrinol Metab. 2007;18(6):252–257.
    1. Amato MC. Endocrine disorders in pediatric - onset Langerhans Cell Histiocytosis. Horm Metab Res. 2006;38(11):746–751.
    1. Makras P. Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH) Neuroradiology. 2006;48(1):37–44.
    1. Donadieu J. Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab. 2004;89(2):604–609.
    1. Alexandraki KI. Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities. QJM. 2008;101(1):31–40.
    1. Makras P. Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2012;58(5):819–822.
    1. Caputo R. A Text Atlas of Histiocytic Syndromes. Informa HealthCare; 1998.
    1. Singhi AD, Montgomery EA. Gastrointestinal tract langerhans cell histiocytosis: A clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305–310.
    1. Yasko AW. Percutaneous techniques for the diagnosis and treatment of localized Langerhans-cell histiocytosis (eosinophilic granuloma of bone) J Bone Joint Surg Am. 1998;80(2):219–228.
    1. Lo WC. Isolated adult Langerhans' cell histiocytosis in cervical lymph nodes: should it be treated? J Laryngol Otol. 2009;123(9):1055–1057.
    1. Hoeger PH. Long term follow up of topical mustine treatment for cutaneous langerhans cell histiocytosis. Arch Dis Child. 2000;82(6):483–487.
    1. Sakai H. Satisfactory remission achieved by PUVA therapy in Langerhans cell hisiocytosis in an elderly patient. J Dermatol. 1996;23(1):42–46.
    1. Imafuku S. Cutaneous Langerhans cell histiocytosis in an elderly man successfully treated with narrowband ultraviolet B. Br J Dermatol. 2007;157(6):1277–1279.
    1. Sander CS, Kaatz M, Elsner P. Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide. Dermatology. 2004;208(2):149–152.
    1. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;48(1):44–49.
    1. Chu A. Dermatological Aspects and Presentation of an Adult Clinic - Oral Presentation at the Annual Meeting of the Histiocyte Society, Vienna. 2011.
    1. Steen AE. Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. Br J Dermatol. 2001;145(1):137–140.
    1. Cantu MA. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7(8):e43257.
    1. Derenzini E. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol. 2010;21(6):1173–1178.
    1. Montella L. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab. 2009;27(1):110–113.
    1. Reichle A. Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults. Br J Haematol. 2005;128(5):730–732.
    1. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. 2005;6(14):2435–2441.
    1. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. N Engl J Med. 2004;351(10):1034–1035.
    1. Janku F. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010;28(31):e633–e636.
    1. Ingram W. Reduced-intensity conditioned allogeneic haematopoietic transplantation in an adult with Langerhans' cell histiocytosis and thrombocytopenia with absent radii. Bone Marrow Transplant. 2006;37(7):713–715.
    1. Xicoy B. [Sustained remission in an adult patient with Langerhans cell histiocytosis following T-cell depleted allogenic cell transplantation] Med Clin (Barc) 2006;127(18):716.
    1. Rodriguez-Galindo C. Clofarabine in refractory Langerhans cell histiocytosis. Pediatr Blood Cancer. 2008;51(5):703–706.
    1. Saven A, Burian C. Cladribine activity in adult langerhans-cell histiocytosis. Blood. 1999;93(12):4125–4130.
    1. Atalar B. Adult langerhans cell histiocytosis of bones : a rare cancer network study. Acta Orthop Belg. 2010;76(5):663–668.
    1. Gaundong Mbethe GL. [Multifocal Langerhans cell histiocytosis of bone: indications for radiotherapy] Cancer Radiother. 2010;14(8):759–762.
    1. Brady LW. In: Langerhans Cell Histiocytosis. Olschewski T, Seegenschmiedt MH, Micke O, editor. Springer Verlag; 2008. Langerhans Cell Histiocytosis; pp. 397–423.
    1. Greenberger JS. Radiation therapy in patients with histiocytosis: management of diabetes insipidus and bone lesions. Int J Radiat Oncol Biol Phys. 1979;5(10):1749–1755.
    1. Heyd R. Radiotherapy in Langerhans-cell histiocytosis. 2 case reports and review of the literature. Rontgenpraxis. 2000;53(2):51–61.
    1. Micke O, Seegenschmiedt MH. Consensus guidelines for radiation therapy of benign diseases: a multicenter approach in Germany. Int J Radiat Oncol Biol Phys. 2002;52(2):496–513.
    1. Cassady JR. Current role of radiation therapy in the management of histiocytosis-X. Hematol Oncol Clin North Am. 1987;1(1):123–129.
    1. Grois N. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain. 2005;128(Pt 4):829–838.
    1. Grois N. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–881. 881 e1.
    1. Idbaih A. Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer. 2004;43(1):55–58.
    1. Imashuku S. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr Blood Cancer. 2008;50(2):308–311.
    1. Chohan G. Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. J Neurol Neurosurg Psychiatry. 2012;83(5):573–575.
    1. Allen CE. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010;54(3):416–423.
    1. Allen CE. Personal communication about. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. 2010.
    1. Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. 2006;27(6):1272–1285.
    1. Watanabe R. Clinico-epidemiological features of pulmonary histiocytosis X. Intern Med. 2001;40(10):998–1003.
    1. Vassallo R. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 2002;346(7):484–490.
    1. Tazi A, Marc K, Dominique S, de Bazelaire C, Crestani B, Chinet T, Israel-Biet D, Cadranel J, Frija J, Lorillon G, Valeyre D, Chevret S. Serial CT and lung function testing in pulmonary Langerhans cell histiocytosis. Eur Respir J. 2012;40(4):905–912.
    1. Auerswald U, Barth J, Magnussen H. Value of CD-1-positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X. Lung. 1991;169(6):305–309.
    1. Lepavec J, Lorillon G, Jaïs X, Tcherakian C, Feuillet S, Dorfmüller P, Simonneau G, Humbert M, Tazi A. Pulmonary Langerhans Cell Histiocytosis associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest. 2012.
    1. Lazor R. Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy. Thorax. 2009;64(3):274–5.
    1. Lorillon G. Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med. 2012;186(9):930–2.
    1. Mendez JL. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest. 2004;125(3):1028–32.
    1. Dauriat G. Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis. Transplantation. 2006;81(5):746–50.
    1. Ananthakrishnan S. Diabetes insipidus in pregnancy: etiology, evaluation, and management. Endocr Pract. 2009;15(4):377–82.
    1. DiMaggio LA, Lippes HA, Lee RV. Histiocytosis X and pregnancy. Obstet Gynecol. 1995;85(5 Pt 2):806–9.
    1. Sharma R, Maplethorpe R, Wilson G. Effect of pregnancy on lung function in adult pulmonary Langerhans cell histiocytosis. J Matern Fetal Neonatal Med. 2006;19(1):67–8.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi